Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2006.072801v1, 2006; 10.1373/clinchem.2006.072801
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.072801v1
52/11/2141    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, O. T.M.
Right arrow Articles by Herold, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, O. T.M.
Right arrow Articles by Herold, D. A.

Received on May 1, 2006
Accepted on August 30, 2006

Oak Ridge Conference

Chip Electrophoresis as a Method for Quantifying Total Microalbuminuria

Owen T.M. Chan 1 David A. Herold 1*

1 Department of Pathology, VA San Diego Healthcare System, San Diego, CA, and Department of Pathology, University of California, San Diego School of Medicine, La Jolla, CA

* To whom correspondence should be addressed. E-mail: ochan{at}ucsd.edu.

Background: Microalbuminuria is an important prognostic marker in diabetic nephropathy and cardiovascular disease. Initially, most commercial assays used immunoreactivity to quantify microalbuminuria; however, size-exclusion HPLC demonstrated the existence of nonimmunoreactive forms of albumin that may not be detected by immunoassay. Recent liquid chromatography tandem mass spectrometry analyses suggested that size-exclusion HPLC gave higher results attributable to other urine proteins coeluting with albumin. We describe an assay that measures total microalbuminuria (immunoreactive and nonimmunoreactive) without any considerable interference from other common urine proteins.

Methods: We used an automated chip electrophoresis system that utilizes microfluidic separation technology and fluorescent sample detection. Each albumin specimen was mixed with the manufacturer's sample buffer in addition to a chicken albumin internal calibrator and then electrophoresed without additional reducing agents.

Results: With variable concentrations of bovine serum albumin normalized to a chicken albumin internal calibrator, the electrophoresis system was best fit with a polynomial (R2=0.9997; concentration range, 5-300 mg/L). The lower limit of detection was 5 mg/L. Interchip and intrachip variation studies conducted on patient urine demonstrated CVs of 3%-13%. The introduction of potentially interfering agents (i.e., molecular analytes, nonalbumin proteins) did not alter precision. Compared with immunoassay, the chip electrophoresis identified higher microalbuminuria concentrations in all urine samples. The method also clearly resolved the albumin peak from interfering proteins.

Conclusions: Unlike immunoassay, chip electrophoresis can detect both immunoreactive and nonimmunoreactive forms of albumin. This system is a simple, robust method to quantify microalbuminuria with good sensitivity, precision, and accuracy.




The following articles in journals at HighWire Press have cited this article:


Home page
Nephrol Dial TransplantHome page
C. Granier, K. Makni, L. Molina, B. Jardin-Watelet, H. Ayadi, and F. Jarraya
Gene and protein markers of diabetic nephropathy
Nephrol. Dial. Transplant., March 1, 2008; 23(3): 792 - 799.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
D. Sviridov, S. K. Drake, and G. L. Hortin
Reactivity of Urinary Albumin (Microalbumin) Assays with Fragmented or Modified Albumin
Clin. Chem., January 1, 2008; 54(1): 61 - 68.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American Association for Clinical Chemistry.